{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chionh F"],"funding":["National Health and Medical Research Council"],"pagination":["1238"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8786898"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["The phase III MAX clinical trial randomised patients with metastatic colorectal cancer (mCRC) to receive first-line capecitabine chemotherapy alone or in combination with the anti-VEGF-A antibody bevacizumab (± mitomycin C). We utilised this cohort to examine whether single nucleotide polymorphisms (SNPs) in VEGF-A, VEGFR1, and VEGFR2 are predictive of efficacy outcomes with bevacizumab or the development of hypertension. Genomic DNA extracted from archival FFPE tissue for 325 patients (69% of the MAX trial population) was used to genotype 16 candidate SNPs in VEGF-A, VEGFR1, and VEGFR2, which were analysed for associations with efficacy outcomes and hypertension. The VEGF-A rs25648 'CC' genotype was prognostic for improved PFS (HR 0.65, 95% CI 0.49 to 0.85; P = 0.002) and OS (HR 0.70, 95%"],"journal":["Scientific reports"],"pubmed_title":["VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer."],"pmcid":["PMC8786898"],"funding_grant_id":["1017737","1048088"],"pubmed_authors":["Williams DS","Scott AM","Weickhardt AJ","Gebski V","Wilson K","Bruhn MA","Simes J","Lee CK","Mooi JK","Chueh AC","Chionh F","Hardingham JE","Tebbutt NC","Al-Obaidi SJ","Price TJ","Mariadason JM"],"additional_accession":[]},"is_claimable":false,"name":"VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.","description":"The phase III MAX clinical trial randomised patients with metastatic colorectal cancer (mCRC) to receive first-line capecitabine chemotherapy alone or in combination with the anti-VEGF-A antibody bevacizumab (± mitomycin C). We utilised this cohort to examine whether single nucleotide polymorphisms (SNPs) in VEGF-A, VEGFR1, and VEGFR2 are predictive of efficacy outcomes with bevacizumab or the development of hypertension. Genomic DNA extracted from archival FFPE tissue for 325 patients (69% of the MAX trial population) was used to genotype 16 candidate SNPs in VEGF-A, VEGFR1, and VEGFR2, which were analysed for associations with efficacy outcomes and hypertension. The VEGF-A rs25648 'CC' genotype was prognostic for improved PFS (HR 0.65, 95% CI 0.49 to 0.85; P = 0.002) and OS (HR 0.70, 95%","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2026-05-09T02:37:34.11Z","creation":"2022-02-11T15:50:07.262Z"},"accession":"S-EPMC8786898","cross_references":{"pubmed":["35075138"],"doi":["10.1038/s41598-021-03952-y"]}}